Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aquestive Therapeutics ( (AQST) ) just unveiled an announcement.
On March 16, 2026, Aquestive Therapeutics agreed that longtime Chief Legal Officer, Chief Compliance Officer and Corporate Secretary Lori J. Braender would step down from her legal and compliance posts and cease being an executive officer effective April 2, 2026, while remaining Corporate Secretary. Under a separation agreement, she will receive salary continuation through May 7, 2026, bonus-based cash severance, extended health and life benefits, and accelerated vesting of equity awards, and she will keep change-in-control severance protections tied to her pre-May 2026 compensation.
In a parallel move, Aquestive set Braender’s new compensation at $15,000 per month for her continuing Corporate Secretary role and confirmed the appointment of Day Pitney partner Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer, effective April 2, 2026. Zalewski, a seasoned life sciences lawyer who has advised the company externally, will receive a significant inducement package of restricted stock units and stock options, signaling Aquestive’s effort to bolster its legal and compliance leadership as it advances its Anaphylm oral epinephrine program and broader pipeline.
Aquestive announced these leadership changes in a press release dated March 20, 2026, underscoring continuity in corporate governance while transitioning its top legal role. The structured handover, retention of Braender as Corporate Secretary, and equity-based incentives for Zalewski suggest a focus on regulatory readiness and strategic support during a critical growth phase for the company’s allergy and dermatology portfolio.
The most recent analyst rating on (AQST) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.
Spark’s Take on AQST Stock
According to Spark, TipRanks’ AI Analyst, AQST is a Neutral.
AQST scores low primarily due to weak financial performance—negative gross profit, widening losses, ongoing cash burn, and negative equity. Offsetting this somewhat are modestly improving technical momentum and a cautiously optimistic regulatory/financing roadmap from the latest earnings call, but valuation remains difficult to support given continuing losses and no dividend.
To see Spark’s full report on AQST stock, click here.
More about Aquestive Therapeutics
Aquestive Therapeutics, Inc. is a New Jersey-based pharmaceutical company focused on advancing medicines through proprietary oral film and other delivery technologies. It develops its own products and operates as a contract development and manufacturing organization, exclusively producing four commercialized PharmFilm-based medicines for licensees, and is advancing Anaphylm for severe allergic reactions and AQST-108 for dermatological uses.
Average Trading Volume: 4,848,443
Technical Sentiment Signal: Sell
Current Market Cap: $495.5M
For detailed information about AQST stock, go to TipRanks’ Stock Analysis page.